|
시장보고서
상품코드
2049316
혈역학 모니터링 시장 규모, 점유율, 동향 및 예측 : 제품별, 모니터링별, 최종사용자별, 지역별(2026-2034년)Hemodynamic Monitoring Market Size, Share, Trends and Forecast by Product, Monitoring, End-User, and Region, 2026-2034 |
||||||
세계의 혈역학 모니터링 시장 규모는 2025년에 12억 4,450만 달러로 평가되었습니다. 향후 IMARC Group은 2026년부터 2034년까지 CAGR 3.82%를 기록하며 2034년까지 시장 규모가 17억 6,230만 달러에 달할 것으로 예측하고 있습니다. 북미가 시장을 주도하고 있으며, 2025년에는 35%라는 큰 시장 점유율을 차지하고 있습니다. 높은 의료비, 선진화된 병원 인프라, 모니터링 기술의 보급, 숙련된 전문가의 존재, 그리고 강력한 규제적 지원 등이 혈역학 모니터링 시장의 점유율 확대에 기여하는 요인 중 일부입니다.
이 시장은 몇 가지 주요 요인에 의해 주도되고 있습니다. 심혈관계 질환 및 호흡기질환의 발생률이 증가함에 따라 중환자 치료의 고도화된 모니터링 시스템에 대한 수요가 증가하고 있습니다. 고령화와 수술 건수의 증가도 이러한 수요에 기여하고 있습니다. 병원과 중환자실에서는 환자의 예후를 개선하기 위해 실시간 정확한 모니터링을 우선시하고 있습니다. 합병증과 회복 기간을 단축할 수 있어 최소침습 및 비침습적 기술이 널리 보급되고 있습니다. 센서, 데이터 분석, 무선 연결 기술의 발전으로 이러한 시스템은 더욱 효율적이고 사용하기 쉬워졌습니다. 또한, 의료 인프라에 대한 정부 투자와 조기 진단 및 예방 의료에 대한 관심이 높아지면서 혈역학 모니터링 시장의 성장을 뒷받침하고 있습니다. 의료 시스템이 환자 관리의 개선을 추진함에 따라 급성기 및 외래 진료 환경 모두에서 혈역학 모니터링 도구의 도입은 앞으로도 계속 확대될 것으로 예상됩니다.
미국에서는 합병증을 예측하고 실시간 의사결정을 지원할 수 있는 AI 기반 모니터링 플랫폼이 주목받고 있습니다. 뇌혈류 지표, 음성 및 제스처 조작, 맞춤형 인터페이스와 같은 고급 기능은 첨단 급성기 의료 현장에서 임상 효율성을 높이고 치료 결과를 개선하는 보다 스마트하고 반응성이 뛰어난 도구로의 전환을 반영하고 있습니다. 예를 들어, 2025년 4월 BD는 AI를 탑재한 혈역학 모니터링 플랫폼 'HemoSphere Alta'를 출시했습니다. 본 제품은 혈류 안정성을 평가하는 뇌 자동조절지수(CAI)와 저혈압을 예측하는 소프트웨어를 갖추고 있습니다. 이 시스템은 맞춤형 터치스크린, 음성 및 제스처 조작을 통해 임상의의 워크플로우를 효율화하여 환자 치료를 개선하는 것을 목표로 합니다.
심장 관련 합병증 증가로 인한 모니터링 이용률 증가
고혈압성 심장질환의 지속적 발생과 관련 사망 사례가 증가함에 따라 정확한 심혈관 평가에 대한 의료적 요구가 증가하고 있습니다. 혈압 관리 미흡으로 인한 합병증에 직면하는 사람들이 늘어남에 따라 병원과 의료 시설에서는 조기 개입을 더욱 중요하게 여기고 있습니다. 혈역학 모니터링 시장 동향은 특히 만성 심장병 환자의 지속적인 모니터링이 중환자실과 수술 후 회복기에 일상화되고 있음을 반영하고 있습니다. 이러한 변화는 심장 기능에 대한 정확한 실시간 피드백을 제공하는 첨단 시스템의 도입을 촉진하고 있습니다. 의료진이 적시에 위험을 감지하고 개입하는 것을 우선시하는 가운데, 급성기 및 장기 치료 환경에서 정보에 입각한 의사결정을 지원하고 치료 결과를 개선할 수 있는 도구에 대한 수요가 꾸준히 증가하고 있습니다. 업계 보고서에 따르면, 2021년 전 세계 고혈압성 심장병(HHD) 유병자 수는 1,251만 명, 사망자 수는 133만 명으로 집계됐습니다. 2022년에는 유병자 수가 1,301만 명으로 증가하고, 사망자 수는 135만 명으로 꾸준히 증가하고 있습니다.
의료 투자 증가로 모니터링 기술 보급 확대 추진
전 세계 의료비는 경제 생산의 상당 부분을 차지할 정도로 확대되고 있으며, 이는 질병 예방, 환자 안전 및 성과 중심의 의료에 대한 관심이 높아진 것을 반영합니다. 의료에 대한 이러한 광범위한 노력은 조달 전략에 영향을 미쳐 혈역학 모니터링 시장의 전망을 형성하고 있으며, 측정 가능한 임상적 가치를 제공할 수 있는 기술을 위해 더 많은 자원이 투입되고 있습니다. 혈역학 모니터링 시스템은 특히 실시간 심혈관 데이터가 중요한 의사결정의 근거가 되는 첨단 의료 환경에서 필수적인 도구로 인식되고 있습니다. 공공 및 민간 부문의 자금 지원 확대에 따라 병원은 정밀 의료를 지원하고, 대응 시간을 단축하며, 수술 및 집중 치료 중 합병증을 줄일 수 있는 솔루션에 보다 적극적으로 투자할 수 있게 되었습니다. 데이터에 기반한 치료 경로와 자원의 효율적인 활용을 위한 움직임은 첨단 모니터링 기기, 특히 최소침습적이고 디지털 헬스 생태계와 호환되는 기기의 도입을 가속화하고 있습니다. 이러한 변화는 복잡한 사례를 보다 정확하게 관리하기 위해 진단의 명확성과 지속적인 추적에 대한 의존도가 높아지고 있음을 보여줍니다. 예를 들어, 세계경제포럼에 따르면 2021년 세계 의료비는 9조 8,000억 달러에 달해 세계 GDP의 10.3%를 차지하고 있습니다.
통합적이고 사용하기 쉬운 모니터링 플랫폼으로 전환
혈역학 모니터링 분야에서는 컴팩트하고 다기능적인 시스템으로의 움직임이 확대되고 있습니다. 임상의들은 특히 시간과 공간이 제한된 중환자실과 수술실에서 정확성과 사용 편의성을 겸비한 도구를 원하고 있습니다. 이러한 변화에는 여러 모니터링 기술을 하나의 디바이스에 통합하여 개별 설정의 필요성을 줄여주는 플랫폼에 대한 선호도가 높아지는 것도 포함됩니다. 터치스크린 인터페이스, 휴대성이 뛰어난 디자인, 충전식 배터리와 같은 기능은 압박감이 높은 환경에서 유연성과 지속적인 지원을 제공함으로써 많은 사랑을 받고 있습니다. 인터페이스의 간소화와 설정 시간 단축으로 임상 팀이 신속하게 대응할 수 있으며, 다양한 소스의 통합 데이터는 의사결정을 강화합니다. 혈역학 모니터링 시장 예측에 따르면, 급성기 의료 환경의 진화하는 요구에 부응하는 보다 스마트하고 적응력이 뛰어난 도구를 통해 워크플로우와 환자 안전을 모두 개선하는 데 초점을 맞추고 있습니다. 예를 들어, 2024년 7월, 게팅게는 CE 인증을 획득한 첨단 혈행 모니터링 플랫폼 'Pulsiocare'를 출시했습니다. PiCCO와 ProAQT의 기술을 하나의 모바일 모니터에 통합한 것으로, 충전식 배터리, 터치스크린, 직관적인 사용자 인터페이스를 갖추고 있으며 중환자실 및 수술실 환경에 적합하도록 설계되었습니다.
The global hemodynamic monitoring market size was valued at USD 1,244.5 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 1,762.3 Million by 2034, exhibiting a CAGR of 3.82% during 2026-2034. North America dominated the market, holding a significant market share of 35% in 2025 . High healthcare spending, advanced hospital infrastructure, widespread adoption of monitoring technologies, skilled professionals, and strong regulatory support are some of the factors contributing to the hemodynamic monitoring market share.
The market is driven by several key factors. There's a growing demand for advanced monitoring systems in critical care due to the rising incidence of cardiovascular and respiratory diseases. An aging population and increased surgical procedures contribute to this demand. Hospitals and ICUs are prioritizing real-time, accurate monitoring to improve patient outcomes. Minimally invasive and non-invasive technologies are gaining popularity, as they reduce complications and recovery time. Technological improvements in sensors, data analytics, and wireless connectivity are making these systems more efficient and user-friendly. Additionally, government investments in healthcare infrastructure and an increased focus on early diagnosis and preventive care are supporting hemodynamic monitoring market growth. As healthcare systems push for better patient management, the adoption of hemodynamic monitoring tools in both acute and ambulatory settings is expected to continue expanding.
In the United States, AI-powered monitoring platforms are gaining attention for their ability to predict complications and support real-time decision-making. Advanced features like cerebral blood flow indicators, voice and gesture controls, and customizable interfaces reflect a shift toward smarter, more responsive tools that enhance clinical efficiency and improve outcomes in high-acuity care settings. For instance, in April 2025, BD launched HemoSphere Alta, an AI-powered hemodynamic monitoring platform. It features a cerebral autoregulation index (CAI) for blood flow stability and predictive software for hypotension. The system enhances clinician workflows with a customizable touchscreen, voice, and gesture controls, aiming to improve patient care.
Growing Burden of Heart-Related Complications Driving Monitoring Use
Persistent cases of hypertensive heart conditions and related deaths have reinforced the medical need for precise cardiovascular assessment. As more individuals face complications linked to unmanaged blood pressure, hospitals and care centers are placing stronger emphasis on early-stage intervention. The hemodynamic monitoring market trend reflects that continuous patient tracking, especially for those with chronic cardiac issues, is becoming routine in intensive care and surgical recovery. This shift is encouraging the adoption of advanced systems that offer accurate, real-time feedback on heart function. With clinicians prioritizing timely risk detection and intervention, demand is steadily building for tools that can support informed decisions and improve outcomes across both acute and long-term care settings. As per an industry report, in 2021, global hypertensive heart disease (HHD) had a prevalence of 12.51 Million and a mortality rate of 1.33 Million. By 2022, the prevalence rose to 13.01 Million, with a mortality rate of 1.35 Million, showing consistent figures.
Rising Healthcare Investment Fuels Monitoring Technology Uptake
Global health spending has grown to occupy a substantial portion of economic output, reflecting increased attention to disease prevention, patient safety, and outcome-driven care. This broader commitment to healthcare is shaping the hemodynamic monitoring market outlook by influencing procurement strategies, with more resources being directed toward technologies that can deliver measurable clinical value. Hemodynamic monitoring systems are increasingly viewed as essential tools, especially in high-dependency environments where real-time cardiovascular data informs critical decisions. As funding expands across both public and private sectors, hospitals are better equipped to invest in solutions that support precision medicine, improve response times, and reduce complications during surgical or intensive care. The push for data-informed care pathways and better resource utilization is accelerating the integration of advanced monitoring devices, especially those that are minimally invasive and compatible with digital health ecosystems. This shift points to growing reliance on diagnostic clarity and continuous tracking to manage complex cases with greater accuracy. For example, in 2021, global health spending reached an astounding USD 9.8 Trillion, representing 10.3% of the world's GDP, according to the World Economic Forum.
Shift toward Integrated and User-Friendly Monitoring Platforms
There is a growing movement toward compact, multifunctional systems in hemodynamic monitoring. Clinicians are seeking tools that merge accuracy with ease of use, especially in critical care and operating rooms where time and space are limited. The shift includes increased preference for platforms that combine multiple monitoring technologies in one device, reducing the need for separate setups. Features like touchscreen interfaces, mobile design, and rechargeable power are gaining traction, offering flexibility and continuous support in high-pressure settings. Simpler interfaces and faster setup times help clinical teams respond quickly, while integrated data from various sources enhances decision-making. As per the hemodynamic monitoring market forecast, the focus is clearly on improving both workflow and patient safety through smarter, more adaptable tools that meet the evolving demands of acute care environments. For instance, in July 2024, Getinge launched Pulsiocare, an advanced hemodynamic monitoring platform with a CE certificate. It combines PiCCO and ProAQT technologies into a single mobile monitor with a rechargeable battery, touchscreen, and an intuitive user interface, designed for critical care and operating room environments.
Monitors stood as the largest product in 2025, holding around 63% of the market. These devices provide continuous, real-time tracking of cardiovascular parameters such as blood pressure, cardiac output, and oxygen levels, which are essential for managing critically ill patients. Hospitals and emergency care units rely on these monitors to make fast, informed decisions during surgeries, trauma, or intensive care. The demand is increasing due to rising cardiovascular disease cases, expanding ICU admissions, and the shift toward minimally invasive procedures that still require detailed monitoring. Technological improvements like wireless connectivity and integration with electronic health records also make these systems more attractive, supporting broader adoption across healthcare facilities. As a result, monitors are a key revenue-driving segment in this space.
Invasive monitoring led the market in 2025 due to its accuracy and reliability in critical care. These systems involve the insertion of catheters or sensors directly into the body, allowing precise measurement of parameters like arterial pressure, central venous pressure, and pulmonary artery pressure. Clinicians prefer invasive methods for high-risk surgeries, trauma cases, and severe cardiac conditions, where non-invasive tools may not provide sufficient data. The growing number of complex surgical procedures, especially in cardiac and transplant units, is boosting demand. Advancements in catheter design and integration with digital monitoring platforms have also improved safety and usability, leading to higher adoption in operating rooms and ICUs across both developed and emerging healthcare systems.
Hospitals led the market with around 43.2% of market share in 2025, owing to the high volume of critical care, surgical, and emergency procedures performed in these settings. Hospitals have the infrastructure and trained personnel to support invasive and non-invasive monitoring technologies, making them the primary users of advanced hemodynamic systems. Rising admissions for cardiovascular diseases, sepsis, and multi-organ failure cases drive the need for continuous and accurate monitoring. Government investments in hospital infrastructure, especially in emerging economies, further support adoption. Integration of monitoring systems with hospital information systems improves workflow and patient management, encouraging upgrades. As patient loads grow and clinical demands increase, hospitals continue to be the leading buyers of hemodynamic monitoring equipment.
In 2025, North America accounted for the largest market share of 35% due to a combination of advanced healthcare infrastructure, high healthcare spending, and early adoption of innovative medical technologies. The region has a large base of critical care and surgical procedures, which increases the need for precise monitoring tools. The presence of major medical device manufacturers, strong distribution networks, and continuous investment in research and development contribute to market leadership. Additionally, the rising prevalence of cardiovascular and respiratory diseases, especially among the aging population, drives demand for both invasive and non-invasive hemodynamic monitoring systems. Favorable reimbursement policies, widespread use of electronic health records, and skilled healthcare professionals further support adoption. The U.S. accounts for the largest share within the region, reflecting its robust hospital networks and ongoing emphasis on improving patient outcomes through advanced monitoring solutions.
UNITED STATES HEMODYNAMIC MONITORING MARKET ANALYSIS
In 2025, the United States accounted for 88.1% of the market share in North America. The US hemodynamic monitoring market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and other chronic conditions. The American Heart Association (AHA) reported that in 2022, cardiovascular disease (CVD) caused 941,652 deaths in the U.S. Between 2017 and 2020, 127.9 Million adults had CVD. The total direct and indirect costs of CVD from 2020 to 2021 were USD 417.9 Billion. In line with this, the growing adoption of minimally invasive technologies, enabling safer and more efficient patient care, is propelling the market growth. Additionally, the rising demand for early detection and personalized treatment strategies is fostering market expansion. The ongoing shift toward value-based healthcare models, which prioritize improved patient outcomes, is further encouraging the use of hemodynamic monitoring systems. Furthermore, continual technological advancements in artificial intelligence and machine learning are enhancing data analytics and predictive capabilities, augmenting product sales. Similarly, the aging population's growing healthcare needs promoting demand for intensive care solutions, is strengthening market demand. Moreover, the rising healthcare spending by both public and private sectors supporting the adoption of cutting-edge monitoring systems, is providing an impetus to the market.
EUROPE HEMODYNAMIC MONITORING MARKET ANALYSIS
The European hemodynamic monitoring market is experiencing growth due to the increasing prevalence of cardiovascular diseases (CVDs) and hypertension. In accordance with this, the region's focus on improving patient outcomes through precision medicine is encouraging the adoption of hemodynamic monitoring systems. Similarly, the growing elderly population requiring intensive care is further strengthening market demand. The rise in non-invasive sensor technologies, which offer enhanced accuracy and patient comfort, is fueling market expansion. Additionally, Europe's strong healthcare infrastructure and investments in advanced medical technologies are supporting the widespread use of hemodynamic monitoring devices. As such, in December 2024, the European Investment Bank (EIB) provided EUR 35 Million in financing to GVM Group, supported by InvestEU. The funds will support medical technology development, clinical research, and digital infrastructure improvements across GVM's healthcare facilities, with projects to be completed by 2027. Furthermore, favorable reimbursement policies in countries like Germany and the UK are promoting market development. The increasing emphasis on early detection and prevention of complications is also facilitating market growth. Besides this, the growing number of surgical procedures requiring real-time monitoring is creating lucrative opportunities in the market.
ASIA PACIFIC HEMODYNAMIC MONITORING MARKET ANALYSIS
The market in Asia Pacific is predominantly propelled by the rapid expansion of healthcare infrastructure, which is improving access to advanced medical technologies across the region. In addition to this, the rising prevalence of lifestyle diseases such as diabetes and hypertension is augmenting demand in the market. According to the 2023 Indian Council of Medical Research - India Diabetes (ICMR INDIAB) study, the prevalence of diabetes in India stands at 10.1 crores. Similarly, the growing adoption of smart healthcare technologies, including wearable devices, is contributing to market growth. Furthermore, increasing healthcare expenditure by both governments and private sectors is facilitating the higher implementation of advanced hemodynamic monitoring systems. Likewise, the rising number of surgical procedures and critical care cases in countries like China and India is further propelling the market development. Moreover, the region's heightened focus on improving healthcare quality and patient outcomes through early intervention is impacting the market trends.
LATIN AMERICA HEMODYNAMIC MONITORING MARKET ANALYSIS
In Latin America, the hemodynamic monitoring market is progressing, driven by the increasing healthcare investment from both public and private sectors. Furthermore, the rising awareness about early diagnosis and proactive patient management is fueling market demand. Additionally, the growing prevalence of cardiovascular diseases across the region is contributing to market growth. Apart from this, the expansion of healthcare facilities, especially in emerging markets like Brazil and Mexico, is enhancing access to advanced monitoring technologies, thus expanding the market's scope. Accordingly, in September 2024, Rede D'Or, Brazil's leading hospital group, plans to invest BRL 7.5 Billion by 2028, adding 5,400 beds, increasing capacity by 46%. The expansion will augment efficiency, with the company aiming for 200-bed hospitals and investing BRL 1.5 Million per bed.
MIDDLE EAST AND AFRICA HEMODYNAMIC MONITORING MARKET ANALYSIS
The market in the Middle East and Africa is significantly influenced by increasing government investments in healthcare infrastructure. In parallel, the rising prevalence of chronic diseases like hypertension and diabetes is driving market growth. Industry analysis reported that in Abu Dhabi, the age-adjusted hypertension prevalence increased from 24.5% at baseline to 35.2% in 2023. Also, the proportion of hypertensive patients with controlled blood pressure rose from 61.8% at baseline to 74.3% in 2023. Additionally, the region's growing focus on medical tourism, particularly in countries such as the UAE and Saudi Arabia, is stimulating market appeal. Besides this, the heightened adoption of digital health solutions and telemedicine is improving patient monitoring capabilities, thereby strengthening the market presence.
The market is seeing increased activity across product launches, partnerships, agreements, funding rounds, and R&D efforts. Companies are prioritizing real-time data integration, AI-based analytics, and minimally invasive technologies. Collaborations between device manufacturers and software firms are helping integrate advanced monitoring with existing clinical systems. Strategic agreements are also being used to expand distribution channels and enhance regional presence. Research is focused on improving predictive monitoring and patient outcomes in critical care settings. Government support is driving innovation, especially in public health systems adopting remote or advanced ICU technologies. Among these, product launches and collaborative agreements have become common practices, often used to introduce next-generation platforms or strengthen market positioning without building from scratch.